Lannett Company, Inc. announced the approval of its Abbreviated New Drug Application (ANDA 203046) for generic codeine sulfate tablets, positioning the company to capture market share in the opioid analgesic space. This approval expands the firm's product portfolio and strengthens its ability to address demand in the oral generic opioids sector.